5-Amino-1MQ
5-Amino-1MQ is the fat-loss compound built around a single enzyme switch, NNMT, that the body uses to control how much fat it burns. It works to free up that switch rather than suppress appetite, so the goal is losing fat without the usual hunger fight. People come to it after stimulant-based fat burners left them wired and still hungry, looking for a metabolic push instead. It comes as an oral capsule or a small subcutaneous injection, both taken once a day.
What it does
Fat loss without hunger control
People turn to 5-Amino-1MQ when appetite suppressants and stimulants have not been the right fit, wanting a fat-loss approach that does not run through hunger control. It's taken daily, either as a 50 to 75 mg oral capsule or a 150 to 500 mcg subcutaneous injection, aimed at shifting body composition rather than just the number on the scale. The idea is that it frees up what fat cells need to burn more fuel. That mechanism is proven in mice, not yet in people.
Sources: Neelakantan H, Vance, 2018
Burning fat without eating less
The draw is a fat-loss effect that skips appetite suppression entirely. In the mouse research this compound is built on, obese mice given it daily for 11 days lost weight and fat mass, their fat cells shrank, and their cholesterol dropped, all without eating less, the kind of result people want when dieting alone has stopped working. No human has ever been dosed in a study to confirm the same happens outside a mouse.
Sources: Neelakantan H, Vance, 2018
Capsule or injection, your choice
Some people running 5-Amino-1MQ want to stay pill-only; others already have needles in their routine for other compounds and would rather add one more injection than a new capsule bottle. Either way it is a once-a-day habit, 50 to 75 mg by mouth or 150 to 500 mcg under the skin. Neither number comes from a study that tested dosing in humans; both are what retail sellers currently recommend.
Dosing
Human dosing – No citable dose
No citable figure. No citable human dose exists for 5-Amino-1MQ. This is a case where the correct entry is that there is no citable dose; any specific milligram or microgram figure in circulation should be treated as unsourced.
Community reportedCommunity/vendor dosing, oral50-75 mg/day, once daily, oral
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Ongoing | 50-75 mg/day | once daily, oral | Unsourced1 |
- Not supported by any clinical or preclinical human study; drawn from peptide-retail dosing guides and calculators.
Community reportedCommunity/vendor dosing, injectable subcutaneous150-500 mcg/day, once daily, SC
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Ongoing | 150-500 mcg/day | once daily, SC | Unsourced1 |
- Not supported by any clinical or preclinical human study; drawn from peptide-retail dosing guides and calculators.
Primary structure
Not a peptide, so no residue sequence applies. See the class above for what this compound is.
Full research
Evidence tier
Animal and in-vitro only
The entire efficacy case for 5-Amino-1MQ, including the specific weight-loss and adipocyte findings that drive its retail marketing, rests on mouse studies. No human trial of any kind, efficacy, safety, or pharmacokinetic, has been published; a targeted search for a human clinical trial of 5-Amino-1MQ returned no results.
Identity
| Full name | 5-Amino-1-methylquinolinium (commonly sold as the iodide salt) |
|---|---|
| Class | Small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor (not a peptide) |
| Molecular weight | 174 g/mol |
Mechanism of action
Plain language
NNMT is an enzyme that consumes nicotinamide, a building block the body also uses to make NAD+, and consumes SAM, a methyl-donor molecule used throughout metabolism, particularly in fat tissue. Blocking NNMT is proposed to leave more nicotinamide and SAM available for other uses, which in animal studies increases fat burning and reduces fat storage.
Technical
5-Amino-1MQ binds the NNMT active site as a competitive inhibitor, reducing the rate of nicotinamide methylation to 1-methylnicotinamide. In diet-induced obese mice, adipose-selective NNMT inhibition raised cellular NAD+ and SAM levels, suppressed lipogenesis in adipocytes, and reduced body weight, white adipose mass, and adipocyte size without changing food intake. This entire mechanistic chain, NNMT inhibition to elevated adipocyte NAD+/SAM to reduced lipogenesis to reduced adiposity, is established in mice; it has not been demonstrated in humans, so it should be described as a proposed mechanism for any human benefit, not an established one.
Sources: Neelakantan H, Vance, 2018, PMC6469996, Small molecule
What it’s used for
Off-label / community use
- Marketed and used in the peptide/research-chemical retail community for fat loss and metabolic health, both as oral capsules and as an injectable reconstituted vial. This use is not supported by any published human data; it extrapolates directly from the mouse obesity literature.
Pharmacokinetics
| Human pharmacokinetics |
Not established No citable figure. No published human pharmacokinetic data (absorption, half-life, bioavailability by any route) was identified for 5-Amino-1MQ. No study directly comparing oral versus subcutaneous administration in humans or animals was identified in this research. |
|---|
Reconstitution
Reconstitution does not apply to this compound: No validated human clinical dose exists for 5-Amino-1MQ, so no defensible unit-on-a-U-100-syringe mapping is given. This research document explicitly flags reconstitution data as a genuine gap for this compound: commercially sold research-grade material is available as oral capsules (commonly 50 mg) or as lyophilized powder for reconstitution with bacteriostatic water, but any dose-to-units mapping on vendor pages maps a commercial vial size to an unpublished, community-derived dose, not a clinically validated one.
Storage and post-reconstitution stability
Unopened storage
Vendor sources describe standard peptide-vial handling conventions (frozen lyophilized storage, refrigerated post-reconstitution storage, light protection, avoidance of freeze-thaw), but none of this has been validated against a stability study specific to 5-Amino-1MQ.
Post-reconstitution stability – Not established
Standard peptide-handling conventions described by vendors but not validated for this compound.
No citable figure. No specific post-reconstitution stability figure was found for 5-Amino-1MQ in the sources reviewed.
Safety
Notable risks
- No published human safety data exists (no Phase 1 trial, no case series identified with a verifiable citation). No long-term (multi-year) safety data exists in any species at the doses commonly sold commercially.
- Rodent studies are reported by secondary sources to show negligible toxicity at research doses with no liver enzyme elevations at relevant doses, but this research did not independently verify a primary toxicology citation with quantitative findings.
- Community-reported effects (mild stimulant-like sensations in the first one to two weeks, insomnia if dosed later in the day) are anecdotal, not derived from any controlled study.
Sources
- Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018 Jan;147:141-152. (2018)
- PMC6469996, Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle
This is a research and educational reference, not medical advice. Nothing on this site is a recommendation to use any compound.